Research programme: brain injury therapeutics - Chiesi
Latest Information Update: 13 Jan 2016
At a glance
- Originator Chiesi
- Mechanism of Action Caspase inhibitors; Melatonin receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Brain injuries
Most Recent Events
- 13 Jan 2016 Early research in Brain injuries (In neonates) in Italy (unspecified route) prior to January 2016 (Chiesi pipeline, January 2016)